Understanding Controlled Correspondence: A Key Tool in Generic Drug Development
In the world of generic drug development, clarity is everything. Sponsors depend on timely, accurate guidance from the U.S. Food and Drug Administration (FDA) to make informed technical and regulatory decisions that shape the success of an Abbreviated New Drug Application (ANDA). One of the most important mechanisms for obtaining this clarity is Controlled Correspondence (CC)—a formal pathway for submitting written inquiries to the FDA.
With the release of FDA’s March 2024 final guidance, “Controlled Correspondence Related to Generic Drug Development,” the expectations and processes around CC are clearer than ever.
What Is Controlled Correspondence?
Controlled correspondence is a written inquiry submitted by or on behalf of a generic drug manufacturer seeking FDA clarification on a specific scientific or regulatory issue related to generic drug development.
Unlike informal inquiries, CCs follow established review timelines and are managed by the Office of Generic Drugs (OGD) within FDA’s Center for Drug Evaluation and Research (CDER). CCs are appropriate for questions involving:
- Drug substance or drug product chemistry
- Bioequivalence approaches
- Interpretation of published guidance
- Post approval submission requirements approval submission requirements ‑approval submission requirements
CCs are not intended for complex scientific issues requiring a pre-ANDA meeting, or matters related to applications already under review.
Why Controlled Correspondence Matters
For generic drug sponsors, CCs are invaluable because they:
- Reduce regulatory uncertainty before significant development investment
- Allow sponsors to confirm expectations around formulation, inactive ingredients, dissolution methods and BE study design
- Support timely, high quality ANDA submissions
- Improve communication efficiency between industry and FDA under GDUFA commitments
In FY 2024 alone, FDA processed 2,792 controlled correspondences, highlighting the heavy reliance on this pathway.
The March 2024 FDA Final Guidance: What’s New?
The latest guidance replaces the 2020 version and incorporates public comments from 2022. It clarifies several core elements:
1. Levels of Controlled Correspondence (GDUFA III)
FDA introduced Level 1 and Level 2 CC categories, each with distinct scopes and response timelines:
- Level 1: Response goal within 60 days
Level 1 Controlled Correspondence applies to less complex issues that can be addressed through straightforward clarifications, limited additional analyses, or minimal data submission.
Level 1 CC is defined as correspondence submitted to the FDA, by or on behalf of a generic drug manufacturer or related industry, that:
- Requests information on a specific element of generic drug product development, including:
a. Prior to ANDA submission
b. Following a Product-Specific Guidance (PSG) teleconference, when further FDA feedback is sought
c. After issuance of a Complete Response Letter (CRL) or tentative approval
d. After ANDA approval - Concerns post approval submission requirements that:
a. Are not covered under the CDER (Center for Drug Evaluation and Research) post approval changes guidance, and
b. Are not specific to an ANDA
- Level 2: Response goal within 90 days
Level 2 Controlled Correspondence applies to more complex or substantive issues that require significant data review, additional studies, or extensive labeling or manufacturing considerations.
Level 2 CC is defined as correspondence submitted to the FDA, by or on behalf of a generic drug manufacturer or related industry, that:
- Requests review of clinical content.
- Requests a Covered Product Authorization to secure sufficient quantities of a REMS (Risk Evaluation and Mitigation Strategies) with ETASU (Elements to Assure Safe Use) product when development or testing does not involve human clinical trials.
- Seeks FDA evaluation of alternative bioequivalence approaches, including pharmacokinetic, in vitro, or clinical
- Requires input from additional FDA offices or centers due to the complexity or specialized nature of the request.
2. Submitting Clarification Requests
Sponsors may now formally request clarification if an FDA response is ambiguous, with FDA aiming to answer 90% within 14 days.
3. Improved Transparency
FDA commits to informing requestors whether their submission is Level 1 or Level 2 and will notify if reclassification occurs during review.
4. Updated Submission Expectations
The guidance provides clearer recommendations for CC scope and content, including for inquiries about:
- Inactive ingredient levels
- Q1/Q2 formulation assessments
- Product quality topics
How to Prepare an Effective Controlled Correspondence
A well written CC increases the chances of receiving a meaningful and timely FDA response. FDA and industry experts recommend including:
- A detailed cover letter outlining the purpose of the inquiry
- A single, clearly defined question—never multiple unrelated queries
- Background information and rationale needed to understand the issue
- Product identification including RLD, dosage form, and strength
- Supporting data or prior FDA communications
For inactive ingredient questions, sponsors should limit inquiries to no more than three ingredients and three proposed levels.
To ensure the FDA can provide a substantive response in a single review cycle, sponsors should supply comprehensive technical context, particularly for analytical methods or bioequivalence study designs.
When to Use Controlled Correspondence vs. Pre-ANDA Meetings
A CC is appropriate when the question is narrow, specific, and answerable in writing, such as:
- Is the proposed inactive ingredient level acceptable?
- Can an alternative in vitro method be used?
- Is a particular dissolution medium aligned with FDA expectations?
A pre-ANDA meeting is advised when:
- Questions are complex and interdisciplinary
- Bioequivalence (BE) or clinical protocols need detailed discussion
- Issues relate to complex generics or REMS (Risk Evaluation and Mitigation Strategies) with ETASU (Elements to Assure Safe Use) requirements
Tips for Successful CC Strategy
- Keep questions focused and factual.
- Provide all data FDA would need to answer without follow-up’s.
- Avoid open-ended questions—propose a specific approach and ask for feedback.
- Check Product Specific Guidance (PSGs) before drafting your question.
- Use CCs early in development to avoid costly reformulations.
- Request clarification when FDA’s reply requires it—this is now formally supported.
The Bottom Line
Controlled Correspondence is an essential, efficient, and increasingly well-structured tool for generic drug developers. With the FDA’s 2024 final guidance, sponsors now have clearer expectations, faster timelines, and improved mechanisms for clarifying responses. By using CC strategically—paired with robust preparation and concise inquiry drafting—sponsors can significantly streamline their ANDA development programs and reduce regulatory uncertainty.
If your team needs help crafting or reviewing controlled correspondence, our regulatory experts can ensure your submissions are both compliant and optimized for successful FDA engagement.
How Voisin Consulting Life Sciences (VCLS) Helps Clients with Controlled Correspondence
Voisin Consulting Life Sciences (VCLS) brings deep experience across ANDA development and FDA interactions. We assist clients by:
- Drafting CC questions that are precise, data supported, and strategically framed supported, and strategically framed‑supported, and strategically framed
- Evaluating PSGs, guidance, and regulatory precedents to align responses with FDA expectations
- Preparing supporting documentation (scientific justification, formulation assessment, BE strategy, etc.)
- Advising on escalation when issues warrant a pre-ANDA meeting instead
- Managing clarification requests when FDA responses introduce ambiguity
Our goal is to help clients get clear, actionable answers from FDA the first time, reducing development delays and strengthening ANDA submission quality.
BLOG POST BY
Questions? Get the answer by our expert team
No two product developments are the same, talk to our experts about your development challenges and we will provide your actional recommendations.